Eye and Vision Research, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Tays Eye Centre, Tampere University Hospital, 33520 Tampere, Finland.
Int J Mol Sci. 2022 Jul 23;23(15):8136. doi: 10.3390/ijms23158136.
Tear fluid forms the outermost layer of the ocular surface and its characteristics and composition have been connected to various ocular surface diseases. As tear proteomics enables the non-invasive investigation of protein levels in the tear fluid, it has become an increasingly popular approach in ocular surface and systemic disease studies. Glaucoma, which is a set of multifactorial diseases affecting mainly the optic nerve and retinal ganglion cells, has also been studied using tear proteomics. In this condition, the complete set of pathophysiological changes occurring in the eye is not yet fully understood, and biomarkers for early diagnosis and accurate treatment selection are needed. More in-depth analyses of glaucoma tear proteomics have started to emerge only more recently with the implementation of LC-MS/MS and other modern technologies. The aim of this review was to examine the published data of the tear protein changes occurring during glaucoma, its topical treatment, and surgical interventions.
泪液形成了眼表面的最外层,其特征和成分与各种眼表面疾病有关。由于泪液蛋白质组学可以非侵入性地研究泪液中的蛋白质水平,因此它已成为眼表面和系统性疾病研究中越来越受欢迎的方法。青光眼是一组影响主要视神经和视网膜神经节细胞的多因素疾病,也已经通过泪液蛋白质组学进行了研究。在这种情况下,眼睛中发生的完整病理生理变化尚不完全清楚,需要用于早期诊断和准确治疗选择的生物标志物。随着 LC-MS/MS 和其他现代技术的实施,最近才开始更深入地分析青光眼的泪液蛋白质组学。本综述的目的是检查青光眼、局部治疗和手术干预过程中发生的泪蛋白变化的已发表数据。